Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 6/20 | 0.61 |
| ▸ | HTR3A | P46098 | 3/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.46 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1689080 | 0.90 | CHRNA7 (0.70) | CHRNA7HTR3ACHRNB4CHRNA3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2113399 | 0.89 | CHRNA7 (0.68) | CHRNA7HTR3ACHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL1753505 | 0.80 | CHRNA7 (0.78) | CHRNA7HTR3ACHRNB4CHRNA3NPC1 | |
| SCHEMBL2641526 | 0.79 | CHRNA7 (0.64) | CHRNA7HTR3ACHRNB4CHRNA3CHRM4 | |
| SCHEMBL1689053 | 0.79 | CHRNA7 (0.61) | CHRNA7HTR3ACHRNB4CHRNA3ALDH1A1 | |
| SCHEMBL2638468 | 0.79 | CHRNA7 (0.57) | CHRNA7HTR3ACHRNB4CHRNA3CHRM4 | |
| SCHEMBL4035464 | 0.78 | CHRNA7 (0.56) | CHRNA7HTR3ACHRNB4CHRNA3CHRM4 | |
| SCHEMBL2638288 | 0.77 | CHRNA7 (0.59) | CHRNA7HTR3ACHRNB4CHRNA3CHRM4 | |
| SCHEMBL2638541 | 0.77 | CHRNA7 (0.78) | CHRNA7HTR3ACHRNB4CHRNA3CHRM4 | |
| SCHEMBL1396007 | 0.77 | CHRNA7 (0.70) | CHRNA7HTR3ACHRNB4CHRNA3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4711391-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| US-7220741-B2 | 1,4-diazabicycloalkane derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 2007-05-22 | — | — | US | claimed |
| EP-1785425-A2 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | NeuroSearch A/S (DK) | 2007-05-16 | — | — | EP | claimed |
| EP-1551835-B1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2007-02-14 | — | — | EP | claimed |
| US-20060122172-A1 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | DANPET AB (SE) | 2006-06-08 | — | — | US | claimed |
| EP-1551835-A1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NeuroSearch A/S (DK) | 2005-07-13 | — | — | EP | claimed |
| WO-2004029053-A1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2004-04-08 | — | — | WO | claimed |
| US-8372832-B2 | 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use | NEUROSEARCH A/S (DK) | 2013-02-12 | — | — | US | disclosed |
| US-20120172353-A1 | 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL COMPOUNDS AND THEIR MEDICAL USE | DANPET AB (SE) | 2012-07-05 | — | — | US | disclosed |
| US-8158619-B2 | 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use | NEUROSEARCH A/S (DK) | 2012-04-17 | — | — | US | disclosed |
| US-20100216780-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | DANPET AB (SE) | 2010-08-26 | — | — | US | disclosed |
| EP-1785425-B1 | 1,4-Diazabicycloalkane derivatives, their preparation and use | NEUROSEARCH AS (DK) | 2009-03-25 | — | — | EP | disclosed |
| US-7220741-B2 | 1,4-diazabicycloalkane derivatives, their preparation and use | NEUROSEARCH A/S (DK) | 2007-05-22 | — | — | US | disclosed |
| EP-1785425-A2 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | NeuroSearch A/S (DK) | 2007-05-16 | — | — | EP | disclosed |
| EP-1551835-B1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH AS (DK) | 2007-02-14 | — | — | EP | disclosed |
| US-20060122172-A1 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | DANPET AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1551835-A1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NeuroSearch A/S (DK) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004029053-A1 | NOVEL 1,4-DIAZABICYCLOALKANE DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216780-A1 | NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL DERIVATIVES AND THEIR MEDICAL USE | CHRNA3, CHRNA6, CHRNA2 | CHRNA7 7/4885HTR3A 63/4885CHRNB4 12/4885 |
| US-20060122172-A1 | Novel 1,4-diazabicycloalkane derivatives, their preparation and use | CHRNA5, CHRNA7, CHRNA6 | CHRNA7 2/4885HTR3A 164/4885CHRNB4 8/4885 |
| US-20120172353-A1 | 1,4-DIAZA-BICYCLO[3.2.2]NONYL OXADIAZOLYL COMPOUNDS AND THEIR MEDICAL USE | CHRNA3, CHRNA6, CHRNA2 | CHRNA7 7/4885HTR3A 64/4885CHRNB4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.